Allan S. Wagman
Corporate Officer/Principal chez RAIN ONCOLOGY INC.
Profil
Allan S.
Wagman is currently the Executive Vice President-Chemistry & Manufacturing at Rain Oncology, Inc. Prior to this, he was the Head-Chemistry & Senior Director-Chemistry at Sagimet Biosciences, Inc. from 2013 to 2018, and the Director-Chemistry at Achaogen, Inc. from 2006 to 2013.
He also worked as the Head-Chemistry at Blanca Pharmaceuticals LLC from 2012 to 2015 and as a Principal Scientist-BioMedical Research at Novartis Institutes for Biomedical Research, Inc. He received his undergraduate degree from Carnegie Mellon University in 1990 and his doctorate degree from The University of Texas at Austin in 1995.
Postes actifs de Allan S. Wagman
| Sociétés | Poste | Début |
|---|---|---|
| RAIN ONCOLOGY INC. | Corporate Officer/Principal | 01/07/2018 |
Anciens postes connus de Allan S. Wagman
| Sociétés | Poste | Fin |
|---|---|---|
| SAGIMET BIOSCIENCES INC. | Corporate Officer/Principal | 01/07/2018 |
| Blanca Pharmaceuticals LLC | Corporate Officer/Principal | 01/11/2015 |
| ACHAOGEN | Corporate Officer/Principal | 01/04/2013 |
Novartis Institutes for Biomedical Research, Inc.
 Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Formation de Allan S. Wagman
| Carnegie Mellon University | Undergraduate Degree |
| The University of Texas at Austin | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SAGIMET BIOSCIENCES INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Achaogen, Inc.
 Achaogen, Inc. Pharmaceuticals: MajorHealth Technology Achaogen, Inc. engages in developing and commercializing innovative antibacterial agents for multi-drug resistant gram-negative infections. The firm is also involved in the development of C-Scape, an orally administered antibiotic to address a serious unmet need for an effective oral treatment for patients with complicated urinary tract infections, including pyelonephritis caused by extended spectrum beta-lactamases producing Enterobacteriaceae. The company was founded by Nathaniel Eames David, Floyd E. Romesberg, and Peter G. Schultz in June 2002 and is headquartered in South San Francisco, CA. | Health Technology |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Commercial Services |
Rain Oncology, Inc.
 Rain Oncology, Inc. BiotechnologyHealth Technology Rain Oncology, Inc. is a clinical-stage precision oncology company, which focuses on developing and implement the precision oncology therapies for patients suffering from cancer. The company was founded by Avanish Vellanki and Robert Doebele in April 2017 and is headquartered in Newark, CA. | Health Technology |
| Blanca Pharmaceuticals LLC |
